ES2111524T3 - Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos. - Google Patents

Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.

Info

Publication number
ES2111524T3
ES2111524T3 ES90113527T ES90113527T ES2111524T3 ES 2111524 T3 ES2111524 T3 ES 2111524T3 ES 90113527 T ES90113527 T ES 90113527T ES 90113527 T ES90113527 T ES 90113527T ES 2111524 T3 ES2111524 T3 ES 2111524T3
Authority
ES
Spain
Prior art keywords
epo
antibodies
peptides
epitope
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90113527T
Other languages
English (en)
Inventor
Mathias Dr Fibi
Werner Dr Stueber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behring Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behring Diagnostics GmbH filed Critical Behring Diagnostics GmbH
Application granted granted Critical
Publication of ES2111524T3 publication Critical patent/ES2111524T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL INVENTO CONCIERNE A LOS PEPTIDOS DE ERITROPOYETINA (EPO) Y A SU UTILIZACION PARA LA OBTENCION DE ANTICUERPOS EPITOPESPECIFICOS ANTI-EPO, LOS CUALES PUEDEN SER POLICLONES (ANTISUEROS) O MONOCLONES. TAMBIEN SE REFIERE EL INVENTO AL USO DE DICHOS ANTICUERPOS PARA LA PURIFICACION DEL EPO, DE LOS DERIVADOS DEL EPO O DE LOS EPO-PEPTIDOS. CONCIERNE TAMBIEN A LOS ANTICUERPOS ANTIIDIOTIPOS QUE IMITAN UNA ZONA RECEPTORA DEL EPO. POR ULTIMO, SE REFIERE A LA UTILIZACION DE REFIERE A LA UTILIZACION DE LOS ANTICUERPOS EPITOPESPECIFICOS ANTI-EPO PARA DETECTAR LA PRESENCIA DE EPO EN MEDICAMENTOS QUE CONTENGAN LOS CITADOS ANTICUERPOS Y PARA DIAGNOSTICAR LA PRESENCIA DE EPO O DE ANTICUERPOS ANTI-EPO.
ES90113527T 1989-07-26 1990-07-14 Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos. Expired - Lifetime ES2111524T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3924746A DE3924746A1 (de) 1989-07-26 1989-07-26 Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper

Publications (1)

Publication Number Publication Date
ES2111524T3 true ES2111524T3 (es) 1998-03-16

Family

ID=6385895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90113527T Expired - Lifetime ES2111524T3 (es) 1989-07-26 1990-07-14 Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.

Country Status (13)

Country Link
US (2) US5106954A (es)
EP (1) EP0410246B1 (es)
JP (1) JP3155002B2 (es)
KR (1) KR0175657B1 (es)
AT (1) ATE161577T1 (es)
AU (1) AU648506B2 (es)
CA (1) CA2021912C (es)
DE (2) DE3924746A1 (es)
DK (1) DK0410246T3 (es)
ES (1) ES2111524T3 (es)
GR (1) GR3026096T3 (es)
IE (1) IE902707A1 (es)
PT (1) PT94813B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932968B1 (en) * 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB2270695B (en) * 1992-09-18 1996-06-05 Oxford Res Support Co Ltd Antibodies that activate plasminogen in the manner of streptokinase
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
ES2210374T3 (es) * 1995-06-07 2004-07-01 Ortho Pharmaceutical Corporation Compuestos y peptidos que se unen al receptor de eritropoyetina.
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
AU744086B2 (en) * 1997-12-03 2002-02-14 Roche Diagnostics Gmbh Erythropoietin with high specific activity
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
KR100524041B1 (ko) * 1999-05-07 2005-10-27 제넨테크, 인크. 신규 침팬지 에리쓰로포이에틴 (chepo) 폴리펩티드 및 이를 코딩하는 핵산
AU766507B2 (en) * 1999-05-07 2003-10-16 Genentech Inc. Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
WO2001077677A1 (en) * 2000-04-05 2001-10-18 Lee Jong Y Detection of erythropoietin and erythtropoietin receptor
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001266557A1 (en) * 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
RU2003125654A (ru) * 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный эритропоэтин (еро) с уменьшенной иммуногенностью
WO2002070009A1 (fr) * 2001-02-27 2002-09-12 Yasuda, Yoshiko Medicaments preventifs/curatifs pour cicatrices hypertrophiques, cheloides et maladies arthritiques chroniques
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
WO2003010173A1 (en) * 2001-07-26 2003-02-06 Tagra Biotechnologies Ltd. Stabilized derivatives of ascorbic acid -3-phosphate
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2310684T3 (es) * 2002-08-09 2009-01-16 Merck Patent Gmbh Epitopes de celulas t en eritropoyetina.
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1608672A4 (en) * 2003-04-02 2007-11-21 Epimmune Inc PEPTIDES, POLYPEPTIDES AND PROTEINS OF REDUCED IMMUNOGENICITY AND METHODS OF PRODUCTION THEREOF
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
CA2586915A1 (en) * 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
US20090118195A1 (en) * 2004-11-10 2009-05-07 Hans-Georg Frank Molecules Which Promote Hematopoiesis
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
EP1907417A2 (en) * 2005-06-23 2008-04-09 AplaGen GmbH Supravalent compounds
KR20170027868A (ko) 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
EP2007791A2 (en) * 2006-03-09 2008-12-31 AplaGen GmbH Modified molecules which promote hematopoiesis
WO2008112703A2 (en) * 2007-03-12 2008-09-18 University Of Utah Research Foundation Compositions and methods for diagnosing and treating diabetic micro vascular complications
NZ587105A (en) * 2008-01-22 2012-09-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
CN107022020A (zh) * 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
MX368067B (es) 2012-12-05 2019-09-18 Novartis Ag Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions

Also Published As

Publication number Publication date
DK0410246T3 (da) 1998-08-31
EP0410246A1 (de) 1991-01-30
AU648506B2 (en) 1994-04-28
ATE161577T1 (de) 1998-01-15
CA2021912A1 (en) 1991-01-27
US5106954A (en) 1992-04-21
DE3924746A1 (de) 1991-01-31
EP0410246B1 (de) 1997-12-29
PT94813B (pt) 1997-04-30
GR3026096T3 (en) 1998-05-29
JP3155002B2 (ja) 2001-04-09
AU5977890A (en) 1991-01-31
IE902707A1 (en) 1991-02-27
US5712370A (en) 1998-01-27
DE59010787D1 (de) 1998-02-05
CA2021912C (en) 2001-11-27
JPH0381294A (ja) 1991-04-05
PT94813A (pt) 1991-03-20
KR910002897A (ko) 1991-02-26
KR0175657B1 (ko) 1999-04-01

Similar Documents

Publication Publication Date Title
ES2111524T3 (es) Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.
ES2082775T3 (es) Anticuerpos de proteinas latentes de papilomavirus humano, sistemas de diagnostico y procedimientos.
WO1996029605A3 (en) Compounds and methods for the dectection of t. cruzi infection
ES2062971T3 (es) Peptidos de la cubierta de htlv iii.
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
WO1989003846A3 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
NO910209D0 (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18 antistoffer.
NO870476D0 (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
DK172686A (da) Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
NO873774D0 (no) Monoklonale eller polyklonale antistoffer.
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
OA09026A (en) Method for detecting antibodies to human immunodeficiency virus.
DE68903882D1 (de) Immunochemisches testverfahren fuer humanen granulozyten-makrophagen-kolonie stimulierenden faktor.
DE69228739T2 (de) Immunoassay und monoklonaler antikörper zum nachweis von diarrhetischem schalentiergift
ES1009600Y (es) Dispositivo de fijacion de elementos sensores.
BR9007071A (pt) Anticorpos de anti-idiotipos que reagem com idiotopos divididos,expressos por linfomas humanos e auto-anticorpo
ZA903854B (en) Diagnostic test for detecting antibodies directed against antigens of one or more related viruses
DK362087D0 (da) Method for a rapid and sensitive detection of early appearing antibodies against retroviruses, as well as igg antibodies against certain retroviruses
NO900092L (no) Et ekspresjonssystem for fremstilling av kimeriske monoklonale antistoffer.
IL83422A (en) Method for the detection of human b lymphotropic virus antibodies
NO912050D0 (no) Sensor for optisk undersoekelse.
DK630189D0 (da) Fremgangsmaade og diagnosesaet til paavisning af antistoffer samt vandig vaskevaeske til brug herved
NO890775D0 (no) Apparat for testing av utblaasningssikring.
IT9006602A0 (it) Test immunoenzimatico per la ricerca e determinazione degli anticorpi anti-ss-dna.
FI905784A (fi) Anordning foer medicinsk anvaendning.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 410246

Country of ref document: ES